the decoy receptor may have a higher affinity for VEGF than the signaling receptor, which is indeed the case
22 More recent research indicates that tirzepatide induces greater reductions in total and visceral fat mass compared with other GLP-1 RAs
2014: Dulaglutide (Trulicity) is approved by the FDA, and is recognized as the first type 2 diabetes drug to reduce the risk of major adverse cardiovascular events (MACE)
These drugs are homologous (53% and 97% respectively) to natural GLP-1, with the added benefit of resistance to degradation by DPP-4 which enhances their half-life
Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients [see Warnings and Precautions (5.6)]
The key is preparation: understanding your medications specific requirements, investing in quality cooling equipment, organizing documentation, and building redundancy into your storage plans